Condition

HER-2 Protein Overexpression

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 11 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials11

Recruiting2

Common interventions17

Lead sponsors shown10

Clinical trials

11 shown

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845 · 2025-01-14

RECRUITING

PRE-ISPY Phase I/II Oncology Platform ProgramNCT05868226 · 2023-02-15

RECRUITING

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 MutationsNCT05904730 · 2023-07-11

COMPLETED

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid TumorsNCT05511844 · 2022-10-03

TERMINATED

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic CancerNCT04602117 · 2021-07-28

WITHDRAWN

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNCT04464967 · 2021-03-01

WITHDRAWN

CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsNCT04660929 · 2021-02-02

UNKNOWN

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid TumorsNCT04650451 · 2020-12-07

SUSPENDED

Testing a New Imaging Agent to Identify CancerNCT04692831 · 2020-11-30

ACTIVE_NOT_RECRUITING

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor CancersNCT03680560 · 2019-03-13

TERMINATED

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1NCT03630809 · 2019-01-10

TERMINATED

Common interventions

TrastuzumabDRUG2 ZanidatamabDRUG2 89Zr-ss-pertuzumab PET/CTCOMBINATION_PRODUCT1 ACTR T Cell ProductBIOLOGICAL1 ALX148DRUG1 AxitinibDRUG1 CetuximabDRUG1 chimeric antigen receptor (CAR) T cell therapyBIOLOGICAL1 CT-0508BIOLOGICAL1 Fam-Trastuzumab Deruxtecan-NxkiDRUG1 HER2 DC1 VaccineBIOLOGICAL1 ORM-5029DRUG1 PembrolizumabBIOLOGICAL1 SNK01BIOLOGICAL1 TTX-MC138DRUG1 TucatinibDRUG1 Vic-trastuzumab duocarmazine (SYD985) + paclitaxelDRUG1

Leading sponsors

QuantumLeap Healthcare Collaborative 2 Bellicum Pharmaceuticals 1 Carisma Therapeutics Inc 1 Cogent Biosciences, Inc. 1 H. Lee Moffitt Cancer Center and Research Institute 1 Jazz Pharmaceuticals 1 Lynkcell Europe 1 Memorial Sloan Kettering Cancer Center 1 NKGen Biotech, Inc. 1 Orum Therapeutics USA, Inc. 1

Trial status mix

TERMINATED3

RECRUITING2

WITHDRAWN2

ACTIVE_NOT_RECRUITING1

COMPLETED1

SUSPENDED1

UNKNOWN1

Phase mix

PHASE19

PHASE24

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.